TAB Clinical Trials

Critical Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of products for respiratory, inflammatory and critical care diseases. The company owns rights to the asthma drug ZYFLO, or zileuton tablets, in addition to other formulations of zileuton throughout the world. ZYFLO is one of the only five lipoxygenase inhibitors approved for marketing by the Untied States Food and Drug Administration and is indicated for the prevention and chronic treatment of asthma in adults and children 12 years of age and older. Critical Therapeutics s commercialization effort for ZYFLO is done with nearly 80 people on the company s specialty sales force. Headquartered in Lexington, Mass., Critical Therapeutics is a privately owned company.

Glycan Therapeutics is a biotechnology company based in Raleigh, NC, specializing in the research and development of innovative therapeutic solutions. With a focus on glycan-based technologies, the company aims to address unmet medical needs and improve patient outcomes through cutting-edge scientific advancements. Generated from their business information

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule drugs that treat cancer, cardiovascular and autoimmune diseases and viral infections. BioCryst uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry and computer modeling. In structure-based drug design, scientists use detailed knowledge of the active sites of protein targets associated with particular diseases to design synthetic compounds that fight the disease. Structure-based drug design aims to create a molecule that will bind to the active site of a targeted enzyme, thereby preventing the normal chemical reaction and ultimately halting the progression of the disease. BioCryst was founded in 1986. The Company's stock is traded on the NASDAQ exchange under the symbol BCRX.